GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Overview


Chris Bruno will speak on a panel for LSPN Connect on the topic of “GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?” Discussion will include an overview of the role of skinny labelling in the US FDA’s regulation of drug products and the implications of the recent GSK v Teva ruling on patent strategies for brand and generic drug manufacturers.

Click here for more information and to register.

Dig Deeper

Chicago, Illinois / Speaking Engagements / May 12, 2022

How to Pitch and Win Business—What Really Works and What Doesn’t

Washington, DC / Speaking Engagements / May 2, 2022

Building and Maintaining an Inclusive Culture

Webinar / Speaking Engagements / February 24, 2022

The State of Asian American and Pacific Islander Attorneys

Get In Touch